Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry

Reuters Events 11 - 22 October, 2021, Virtual
Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a response to the COVID-19 pandemic, by joining the speaker faculty at Reuters Events Pharma Europe 2021.

Reuters Events will bring together another 150 life sciences leaders as speakers, and thousands more executive attendees, to showcase the investments being made as the industry accelerates its digital transformation platform to ensure changes are embedded for long-term value for physicians and patients alike.

Blair Gottscho, Managing Director - Pharma, Reuters Events, said the pharma industry had responded well to the challenges of the pandemic, re-assessed operating models, and have found new ways to deliver for physicians, clinicians, providers, payers and patients alike.

"There is significant investment happening across the industry - in both people and technology - to create long-lasting, integrated and flexible systems and processes, that are helping to build a more sustainable healthcare systems.

"We're proud to be showcasing the best and brightest at Pharma Europe 2021. This is the global home for industry executives to set strategy post-pandemic.” Along with this investment, the industry is experiencing an acceleration in collaboration between functions within organizations. However, the environment for collaboration extends beyond company walls, as companies are increasingly forming partnerships that build value for all healthcare stakeholders.

Josh Bramwell, Head of Europe, Reuters Events, said the industry had stepped up to the challenges that the pandemic has created.

“Companies are now seeing collaboration as a competitive advantage," Bramwell said.

"They've looked to optimise pre-competitive opportunities with industry partners, foster long-term stakeholder partnerships to provide real-world patient value, and remove function silos to deliver an agile and efficient business model. These are the case studies that we'll be highlighting on stage at Pharma Europe 2021."

Reuters Events Pharma Europe has been running for 18 years and was previously known as eyeforpharma Barcelona.

You can learn more about Pharma Europe here: https://reutersevents.com/events/barcelona/

Most Popular Now

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Sandoz announces new global 'Act4Biosimilars' init…

Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called 'Act4Biosimilars' to help address health inequity and ...

Blocking enzyme could hold the key to preventing, …

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

GSK to acquire clinical-stage biopharmaceutical co…

GSK plc (LSE/NYSE: GSK) announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based...

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...